Cargando…
Inotersen: new promise for the treatment of hereditary transthyretin amyloidosis
Hereditary transthyretin amyloidosis is a fatal autosomal dominant disorder characterized by deposition of transthyretin amyloid into the peripheral nervous system, heart, kidney, and gastrointestinal tract. Previous treatments using liver transplantation and small molecule stabilizers were not effe...
Autores principales: | Mathew, Veena, Wang, Annabel K |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6507904/ https://www.ncbi.nlm.nih.gov/pubmed/31118583 http://dx.doi.org/10.2147/DDDT.S162913 |
Ejemplares similares
-
Neuropathy symptom and change: Inotersen treatment of hereditary transthyretin amyloidosis
por: Dyck, P. James B., et al.
Publicado: (2020) -
Inotersen preserves or improves quality of life in hereditary transthyretin amyloidosis
por: Coelho, Teresa, et al.
Publicado: (2019) -
Tegsedi (Inotersen): An Antisense Oligonucleotide Approved for the Treatment of Adult Patients with Hereditary Transthyretin Amyloidosis
por: Gales, Luís
Publicado: (2019) -
The impact of inotersen on Neuropathy Impairment Score in patients with hereditary transthyretin amyloidosis with polyneuropathy
por: Yarlas, Aaron, et al.
Publicado: (2023) -
Population Pharmacokinetic–Pharmacodynamic Modeling of Inotersen, an Antisense Oligonucleotide for Treatment of Patients with Hereditary Transthyretin Amyloidosis
por: Yu, Rosie Z., et al.
Publicado: (2020)